Branched PEG Polymer Conjugate for Sustained Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic biomolecules, such as peptides and proteins, have short plasma half-lives and poor stability, leading to rapid elimination and the need for frequent injections, which increases treatment costs and reduces patient compliance, and PEGylation, while intended to improve stability, often induces anti-PEG antibodies causing immune reactions and reduced efficacy.
Innovation Solution
A thermally responsive polymer-therapeutic molecule conjugate using a backbone of acrylate, methacrylate, or acrylamide monomers with oligoethylene glycol side chains, allowing for a transition temperature between 23° C. and 40° C., forming a depot that sustains release and avoids immune reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If therapeutic biomolecules are covalently attached to linear polyethylene glycol (PEG) moieties to improve plasma half-life and stability, then the duration of action is improved, but anti-PEG antibodies are induced causing immune reactions and accelerated drug clearance
Solution Approach 1:
The patent changes the physical and chemical parameters of the PEG structure by introducing a branched architecture with multiple PEG arms radiating from a central core, rather than using linear PEG chains. This structural parameter change maintains the hydrophilic and stealth properties while reducing immunogenicity. The patent also optimizes the degree of substitution and molecular weight distribution to further tune the immunogenicity profile while maintaining extended plasma half-life.
Solution Approach 2:
The patent creates a composite conjugate structure combining the therapeutic biomolecule with a multifunctional branched PEG carrier that has multiple arms. This composite architecture integrates the pharmacological activity of the therapeutic with the pharmacokinetic benefits of PEGylation, while the unique branched structure reduces recognition by anti-PEG antibodies. The composite material approach allows simultaneous optimization of stability, half-life, and immune compatibility.
2Reliability
If PEGylation is used to improve stability of therapeutic biomolecules, then the reliability is improved, but pre-existing anti-PEG antibodies cause accelerated drug clearance
Solution Approach 1:
The patent modifies the structural parameters of PEG by using a branched architecture with controlled arm lengths and substitution patterns. This parameter optimization maintains the stabilizing effect on the therapeutic biomolecule while reducing the epitope recognition by pre-existing anti-PEG antibodies. The patent fine-tunes the molecular weight and branching density to achieve optimal balance between stability enhancement and immune system evasion.
3Duration of action of moving object
If frequent injections are administered to maintain therapeutic efficacy due to short plasma half-life, then the duration of action is maintained, but patient compliance deteriorates and treatment costs increase
Solution Approach 1:
The patent optimizes the molecular weight and branching architecture of the PEG conjugate to achieve extended plasma half-life, which directly reduces the injection frequency required to maintain therapeutic efficacy. This parameter optimization allows transition from frequent dosing to less frequent dosing schedules, thereby improving patient compliance while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate significantly improves the in vivo efficacy of therapeutics by extending the duration of action, reducing the frequency of injections, and avoiding interactions with pre-existing anti-PEG antibodies, providing a more stable and effective delivery system.
Implementation Method 1
the conjugate has a transition temperature between 23° C. and 40° C.
Data Source
AI summary
Described herein are thermally responsive polymer-therapeutic molecule conjugates comprising a therapeutic molecule conjugated to a thermally responsive polymer with an acrylate, methacrylate, acrylamide, and/or methacrylamide backbone and a plurality of oligoethylene glycol side chains.